SuperworthZevra Therapeutics price to free cash flow ZVRA
Market value divided by free cash flow over the last twelve months, since 2022.
- Today, Oct 23, 2026
- 17.9×
- 4-year median
- 21.1×
- Against its 4-year history
- 21st
- percentile: 0 is its lowest day, 100 its highest
- 4-year range
- 15.0× to 68.9×
- Peer median
- 7.0×
Zevra Therapeutics' price to free cash flow is 17.9× as of Oct 23, 2026.
That is below its 4-year median of 21.1×, lower than on 79% of days in the last 4 years.
Over that time it ranged from 15.0× in May 2022 to 68.9× in Jul 2026.
The median for 10 large drugmakers of a similar size is 7.0×.
Price to free cash flow over time
Year by year
| Year | End of year | Low | High |
|---|---|---|---|
| 2026 so far | 17.9× | 17.9× | 68.9× |
| 2025 | n/m a value too high to mean anything | ||
| 2024 | n/m a value too high to mean anything | ||
| 2023 | n/m a value too high to mean anything | ||
| 2022 | 22.3× | 15.0× | 23.5× |
Against its peers
Companies in Drug Manufacturers - General nearest Zevra Therapeutics' size, closest first, today.
| Company | Price to free cash flow |
|---|---|
| ZVRAZevra Therapeutics | 17.9× |
| IRWDIronwood Pharmaceuticals | n/m |
| PBYIPuma Biotechnology | 13.8× |
| CRMDCorMedix | 2.4× |
| ARVNArvinas | n/m |
| COLLCollegium Pharmaceutical | 2.3× |
| ABUSArbutus Biopharma | n/m |
| AMPHAmphastar Pharmaceuticals | 7.0× |
| OMEROmeros | n/m |
| PCRXPacira BioSciences | 8.1× |
| ANABAnaptysbio | n/m |
| Peer median | 7.0× |
What the price to free cash flow tells you
Market value divided by free cash flow: the cash left after running the business and paying for equipment. Cash is harder to manage than accounting earnings, so many investors trust this more than PE.
Lumpy: a big year of building factories drops cash flow and inflates the ratio without the business getting worse.
More on Zevra Therapeutics
Valuation data, not investment advice. Prices as of . Reported figures come from the company's filings with the SEC.